INVENTISBIO CO., LIMITED

Highlights InventisBio Co., Limited

Equities

688382

CNE100005Q22

End-of-day quote Shanghai S.E. Other stock markets 18:00:00 2024-06-06 EDT			5-day change	1st Jan Change
8.03 ^CNY	+2.03%		-7.81%	-46.96%

04-29	InventisBio Co., Limited Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
04-11	Sino Biopharmaceutical Presents Cancer Drug's Phase-II Clinical Trial Results at AACR 2024	MT

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

InventisBio Co., Limited Reports Earnings Results for the First Quarter Ended March 31, 2024	04-29	CI
Sino Biopharmaceutical Presents Cancer Drug's Phase-II Clinical Trial Results at AACR 2024	04-10	MT
InventisBio Co., Limited Reports Earnings Results for the Full Year Ended December 31, 2023	02-05	CI
InventisBio Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-27	CI
InventisBio, Beida Pharmaceutical Get Registration Certification for Befortinib Mesylate Capsules	23-10-13	MT
InventisBio Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-21	CI
Sino Biopharm Unit Gets Exclusive License to Develop Inventisbio's Cancer Drug	23-08-03	MT
Chia-Tai Tianqing Pharmaceutical Group Co., Ltd Enters into Exclusive License and Cooperation Agreement with Inventisbio Co., Ltd	23-08-03	CI
InventisBio Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-25	CI
InventisBio Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	23-02-27	CI
InventisBio Co., Ltd. has completed an IPO in the amount of CNY 2.0838 billion.	22-07-15	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

+229% on MICROSOFT CORPORATION since our purchase on January 11, 2019

Replicate our performance

fermer